Trials / Completed
CompletedNCT04255979
A Study of HY209 in Healthy Male Volunteers for Sepsis
A Randomized, Double-blind, Placebo-controlled Single Dosing, Dose Escalation Phase I Clinical Trial to Investigate the Safety/Tolerability and Pharmacokinetics of HY209 After Intravenous Administration in Healthy Male Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Shaperon · Industry
- Sex
- Male
- Age
- 19 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
A randomized, double-blind, placebo-controlled single dosing, dose escalation phase I clinical trial to investigate the safety/tolerability and pharmacokinetics of HY209 after intravenous administration in healthy male volunteers
Detailed description
HY209, which is being developed for the treatment of sepsis, inhibits inflammation by promoting the differentiation and division of Myeloid-derived suppressor cells (MDSCs).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HY209 | 6 Subjects will be assigned to drug (HY209) and 2 subjects will be assigned to placebo. |
Timeline
- Start date
- 2019-12-05
- Primary completion
- 2020-06-12
- Completion
- 2020-06-12
- First posted
- 2020-02-05
- Last updated
- 2020-11-30
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT04255979. Inclusion in this directory is not an endorsement.